Delving into the Latest Updates on Guangzhou BioSyngen Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Digestive System Disorders

Hemic and Lymphatic Diseases

CAR-T

TIL therapy

Autologous CAR-T

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	6
Hemic and Lymphatic Diseases	2
Immune System Diseases	2
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

CAR-T	2
T-lymphocyte cell therapy	2
TIL therapy	1
Autologous CAR-T	1

Top 5 Target	Count

CD40L(CD40 ligand)	1
EBV Protein	1

主要目的：评估BST02注射液治疗晚期肝癌受试者的安全性和耐受性。次要目的：评估BST02注射液治疗晚期肝癌受试者的初步有效性；评估BST02注射液的药代动力学（Pharmacokinetics，PK）特征。探索性目的：探索BST02注射液的药效动力学（Pharmacodynamics，PD）特征。

[Translation]

Primary objective: To evaluate the safety and tolerability of BST02 injection in the treatment of subjects with advanced liver cancer. Secondary objective: To evaluate the preliminary efficacy of BST02 injection in the treatment of subjects with advanced liver cancer; to evaluate the pharmacokinetic (PK) characteristics of BST02 injection. Exploratory objective: To explore the pharmacodynamic (PD) characteristics of BST02 injection.

Start Date05 Jul 2024

Sponsor / Collaborator

Guangzhou BioSyngen Co., Ltd.

CTR20240722

/ RecruitingPhase 1

一项观察BRL03注射液治疗EBV阳性晚期实体瘤的初步安全性和有效性的Ⅰ期临床研究

[Translation] A Phase I clinical study to observe the preliminary safety and efficacy of BRL03 injection in the treatment of EBV-positive advanced solid tumors

主要研究目的：评价BRL03注射液的初步安全性和耐受性；次要研究目的：评价BRL03注射液治疗EBV阳性晚期实体瘤受试者初步有效性，评价BRL03注射液的药代动力学(PK）特征；探索性研究目的：探索BRL03注射液的药效动力学（PD）特征，探索肿瘤靶点、PD-L1表达、CPS评分与BRL03注射液疗效及安全性的相关性，评价BRL03注射液的免疫原性，探索血浆中EBV DNA含量与安全性及疗效的相关性，探索RCL的发生情况，探索BRL03生产的可行性。

[Translation]

The main study objectives are to evaluate the preliminary safety and tolerability of BRL03 injection. The secondary study objectives are to evaluate the preliminary efficacy of BRL03 injection in the treatment of subjects with EBV-positive advanced solid tumors, and to evaluate the pharmacokinetic (PK) characteristics of BRL03 injection. The exploratory study objectives are to explore the pharmacodynamic (PD) characteristics of BRL03 injection, explore the correlation between tumor targets, PD-L1 expression, CPS score and the efficacy and safety of BRL03 injection, evaluate the immunogenicity of BRL03 injection, explore the correlation between EBV DNA content in plasma and safety and efficacy, explore the occurrence of RCL, and explore the feasibility of BRL03 production.

Start Date16 May 2024

Sponsor / Collaborator

Guangzhou BioSyngen Co., Ltd.

NCT06104215

/ RecruitingEarly Phase 1IIT

Clinical Study on the Safety and Initial Efficacy of BGT007H Cell Therapy in Patients With Recurrent/Metastatic Refractory Digestive Tract Tumors

This is an exploratory clinical study evaluating the safety and initial efficacy of BGT007H injection in the treatment of recurrent/metastatic/refractory digestive system tumors.

Start Date22 Oct 2023

Sponsor / Collaborator

Affiliated Hospital of Xuzhou Medical University

[+1]

100 Clinical Results associated with Guangzhou BioSyngen Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Guangzhou BioSyngen Co., Ltd.

Login to view more data

1

Literatures (Medical) associated with Guangzhou BioSyngen Co., Ltd.

28 Jun 2023·Journal of biomedical science

Tumor-secreted IFI35 promotes proliferation and cytotoxic activity of CD8⁺ T cells through PI3K/AKT/mTOR signaling pathway in colorectal cancer.

Article

Author: Cheng, Yikan ; Long, Jiahui ; Li, Peisi ; Huang, Wenfeng ; Ye, Shubiao ; Zhou, Dawang ; Zou, Yifeng ; Chen, Yuan ; Ke, Haoxian ; Lin, Zhensen ; Chen, Dongwen ; Huang, Zhihong ; Cai, Jiawei ; Zhang, Xi ; Lan, Ping ; Lin, Yanyun

BACKGROUND:

A large proportion of the patients with cancer do not respond to immunotherapies. Recent studies suggested an important role for tumor-infiltrating cytotoxic T lymphocytes (CTL) in enhancing response to immunotherapy. Here, we aim to identify gene that induce proliferative and cytotoxic states of CD8⁺ T cells, and to investigate its effect on CAR-T cells against colorectal cancer.

METHODS:

Correlation between the expression of IFI35 with the activation and cytotoxicity of CD8⁺ T cells was assessed with TCGA and proteomic databases. Then we constructed murine colon cancer cells over-expressing IFI35 and tested their effect on anti-tumor immunity in both immunodeficient and immunocompetent mouse models. Flow cytometry and immunohistochemistry were performed to assess the immune microenvironment. Western blot analysis was used to identify the potential down-stream signaling pathway regulated by IFI35. We further investigated the efficacy of the rhIFI35 protein in combination with immunotherapeutic treatment.

RESULTS:

The transcriptional and proteomic analysis of the activation and cytotoxicity of CD8⁺ T cells in human cancer samples demonstrated that IFI35 expression is correlated with increased CD8⁺ T cell infiltration and predicted a better outcome in colorectal cancer. The number and cytotoxicity of CD8⁺ T cells were significantly increased in IFI35-overexpressing tumors. Mechanistically, we identified that the IFNγ-STAT1-IRF7 axis stimulated IFI35 expression, and that IFI35-mediated regulation of CD8⁺ T cell proliferation and cytotoxicity was dependent on PI3K/AKT/mTOR signaling pathway in vitro. Furthermore, IFI35 protein enhanced the efficacy of CAR-T cells against colorectal cancer cells.

CONCLUSION:

Our findings identify IFI35 as a new biomarker that can enhance the proliferation and function of CD8⁺ T cells, as well as increase the efficacy of CAR-T cells against colorectal cancer cells.

100 Deals associated with Guangzhou BioSyngen Co., Ltd.

Login to view more data

100 Translational Medicine associated with Guangzhou BioSyngen Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 15 Mar 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

Preclinical

Phase 1

4

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

BRL03	Lymphoma More	Phase 1
BST-02	Hepatocellular Carcinoma More	Phase 1
BRG01 ( EBV Protein )	Epstein-Barr virus positive Lymphoma More	Phase 1
BGT-007	Gastrointestinal Neoplasms More	Early Phase 1
BST008	Liver Cancer More	Preclinical